Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCL), 52 avenue Mounier, 1200 Brussels,(EU), Belgium.
J Mol Cell Cardiol. 2012 Feb;52(2):330-40. doi: 10.1016/j.yjmcc.2011.07.029. Epub 2011 Aug 7.
Cyclic guanosine 3'5'monophosphate (cGMP) is the common downstream second messenger of natriuretic peptides and nitric oxide. In cardiac myocytes, the physiological effects of cGMP are exerted through the activation of protein kinase G (PKG) signaling, and the activation and/or inhibition of phosphodiesterases (PDEs), providing an integration point between cAMP and cGMP signals. Specificity of cGMP signals is achieved through compartmentalization of cGMP synthesis by guanylate cyclases, and cGMP hydrolysis by PDEs. Increasing evidence suggests that cGMP-dependent signaling pathways play an important role in inhibiting cardiac remodeling, through the inhibition Ca(2+) handling upstream of pathological Ca(2+)-dependent signaling pathways. Thus, enhancing cardiac myocyte cGMP signaling represents a promising therapeutic target for treatment of cardiovascular disease. This article is part of a Special Issue entitled "Local Signaling in Myocytes."
环鸟苷酸 3'5' 一磷酸（cGMP）是利钠肽和一氧化氮的常见下游第二信使。在心肌细胞中，cGMP 的生理效应通过蛋白激酶 G（PKG）信号的激活以及磷酸二酯酶（PDEs）的激活和/或抑制来发挥作用，为 cAMP 和 cGMP 信号之间提供了一个整合点。cGMP 信号的特异性是通过鸟苷酸环化酶对 cGMP 合成的区室化和 PDEs 对 cGMP 的水解来实现的。越来越多的证据表明，cGMP 依赖性信号通路通过抑制病理性 Ca(2+)-依赖性信号通路上游的 Ca(2+)处理，在心重构中发挥重要作用。因此，增强心肌细胞 cGMP 信号转导代表了治疗心血管疾病的一个有前途的治疗靶点。本文是题为“心肌细胞中的局部信号”的特刊的一部分。
